The recent deal for Imsidolimab reflects low confidence in the drug's market potential, despite positive phase 3 results. Rosnilimab showed promising trial results but failed to differentiate ...
AnaptysBio (NASDAQ:ANAB – Get Free Report)‘s stock had its “neutral” rating reaffirmed by stock analysts at HC Wainwright in a research report issued on Tuesday,Benzinga reports.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback